Welcome to CCST
CCST provides excellent world class research facilities and the expertise to perform early Phase I and II studies for the pharmaceutical industry. Since the late 1990’s CCST has become a major provider of clinical trials to the pharmaceutical industry. Since the late 1990’s CCST has become a major supplier of clinical trials to the industry. Quality is an integral part of clinical trials and CCST is routinely audited 3 to 4 times per year by Sponsors and we were FDA inspected in May 2017.
For further information, please contact Jo Sanders our Operation Manager firstname.lastname@example.org
Christchurch doctors have, over many years, been involved in a wide range of clinical trials for the pharmaceutical industry. A need was identified for a well designed and dedicated facility to perform Phase I and II pharmacokinetic and pharmacodynamic studies in healthy volunteer and patient populations.
IMPORTANT INFORMATION !!
CCST study information is now emailed out via a email service. Please check your mailing promotions and spam folders for CCST study emails. To ensure you receive your emails from CCST: Add the CCST email address to your Google Contacts or Move your CCST emails to the Primary tab and Gmail will learn that you wish to receive emails from CCST. Thanks for your help !
We have recently mailed out the SIMBA study information. We are expecting a big response so please note it may take us a week or so to get back to you.
Investigating the safety and tolerability of inhaled GDL- 0214
Males and Females
Age: 18 to 65 years
No significant health issues (to be confirmed by the Study doctor)
Investigational Study Drug
Requirements: 4 night in-house stay and 3 clinic visits.
Study to investigate the safety and tolerability of a single dose of the trial drug CMX 521
Gender Males and Females – females need to be of non child bearing potential
Overall Status Recruiting
Study Type Safety and Tolerability of a new medication
Requirements 2 night in stay and 5 clinic visits
Age 18 to 55 Years
Gender Males and Females
No significant health issues (to be confirmed by study doctor)
Study Type: Evaluating equivalence of MSB11456 (Tocilizumab proposed biosimilar) with the Tocilizumab that is approved in both the USA and the EU
Requirements: Single dose of the study drug , 3 night inpatient stay and 10 clinic visits
Please note for this study you need to weigh over 60kg and not be on any medications
Do not hesitate to contact Us!
0800 TO CCST or +64 3 372 9477
+64 3 3729478